Journal
CYTOKINE & GROWTH FACTOR REVIEWS
Volume 12, Issue 1, Pages 33-40Publisher
ELSEVIER SCI LTD
DOI: 10.1016/S1359-6101(00)00021-6
Keywords
cytokine; androgen receptor; signal transduction; chemotherapy; androgen independence
Categories
Funding
- NCI NIH HHS [1P50 CA69568] Funding Source: Medline
- NCRR NIH HHS [T32 RR07008] Funding Source: Medline
- NIA NIH HHS [R01 AG39738] Funding Source: Medline
Ask authors/readers for more resources
Prostate cancer, while initially dependent on androgens fbr proliferation, progresses to an androgen-independent state. Evidence has been accumulating that interleukin-6 (IL-6) may contribute to prostate cancer progression. Serum levels of IL-6 correlate with prostate tumor burden and patient morbidity. The prostate tissue itself appears to be a source of IL-6 and its receptor. Furthermore, experimental data suggest that IL-6 is an autocrine and paracrine growth factor for androgen-independent prostate cancer cell lines. For example, inhibition of IL-6, with anti-IL-6 antibody, sensitizes androgen-independent prostate cancer cells to chemotherapeutic agents in vitro. Finally, IL-6 activates a variety of signal transduction cascades, some which stimulate androgen receptor activity, in prostate cancer cells. These data suggest that targeting IL-6 may have multiple benefits in prostate cancer patients. (C) 2001 Elsevier Science Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available